|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siddiqui SA, Inman BA, Sengupta S, Slezak
JM, Bergstralh EJ, Leibovich BC, Zincke H and Blute ML: Obesity and
survival after radical prostatectomy: A 10-year prospective cohort
study. Cancer. 107:521–529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nolan T and Cogoni C: The long hand of the
small RNAs reaches into several levels of gene regulation. Biochem
Cell Biol. 82:472–481. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu C, Kelnar K, Vlassov AV, Brown D, Wang
J and Tang DG: Distinct microRNA expression profiles in prostate
cancer stem/progenitor cells and tumor-suppressive functions of
let-7. Cancer Res. 72:3393–3404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duan Z, Choy E, Nielsen GP, Rosenberg A,
Iafrate J, Yang C, Schwab J, Mankin H, Xavier R and Hornicek FJ:
Differential expression of microRNA (miRNA) in chordoma reveals a
role for miRNA-1 in Met expression. J Orthop Res. 28:746–752.
2010.
|
|
7
|
Ratert N, Meyer HA, Jung M, Mollenkopf HJ,
Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S and Jung K:
Reference miRNAs for miRNAome analysis of urothelial carcinomas.
PLoS One. 7:e393092012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lang MF, Yang S, Zhao C, Sun G, Murai K,
Wu X, Wang J, Gao H, Brown CE, Liu X, et al: Genome-wide profiling
identified a set of miRNAs that are differentially expressed in
glioblastoma stem cells and normal neural stem cells. PLoS One.
7:e362482012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh
T, Kojima K, Nakashima R, Kitade Y and Naoe T: Role of antioncomirs
miR-143 and -145 in human colorectal tumors. Cancer Gene Ther.
17:398–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B,
Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative
regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Gao JS, Tang X, Tucker LD,
Quesenberry P, Rigoutsos I and Ramratnam B: MicroRNA 125a and its
regulation of the p53 tumor suppressor gene. FEBS Lett.
583:3725–3730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bader AG, Brown D and Winkler M: The
promise of microRNA replacement therapy. Cancer Res. 70:7027–7030.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fendler A, Jung M, Stephan C, Honey RJ,
Stewart RJ, Pace KT, Erbersdobler A, Samaan S, Jung K and Yousef
GM: miRNAs can predict prostate cancer biochemical relapse and are
involved in tumor progression. Int J Oncol. 39:1183–1192.
2011.PubMed/NCBI
|
|
16
|
Leite KR, Tomiyama A, Reis ST,
Sousa-Canavez JM, Sañudo A, Dall'Oglio MF, Camara-Lopes LH and
Srougi M: MicroRNA-100 expression is independently related to
biochemical recurrence of prostate cancer. J Urol. 185:1118–1122.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Long Q, Johnson BA, Osunkoya AO, Lai YH,
Zhou W, Abramovitz M, Xia M, Bouzyk MB, Nam RK, Sugar L, et al:
Protein-coding and microRNA biomarkers of recurrence of prostate
cancer following radical prostatectomy. Am J Pathol. 179:46–54.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schaefer A, Jung M, Mollenkopf HJ, Wagner
I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung
K: Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.
|
|
19
|
Spahn M, Kneitz S, Scholz CJ, Stenger N,
Rüdiger T, Ströbel P, Riedmiller H and Kneitz B: Expression of
microRNA-221 is progressively reduced in aggressive prostate cancer
and metastasis and predicts clinical recurrence. Int J Cancer.
127:394–403. 2010.
|
|
20
|
Tong AW, Fulgham P, Jay C, Chen P, Khalil
I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J: MicroRNA
profile analysis of human prostate cancers. Cancer Gene Ther.
16:206–216. 2009.
|
|
21
|
Mackillop WJ, Ciampi A, Till JE and Buick
RN: A stem cell model of human tumor growth: Implications for tumor
cell clonogenic assays. J Natl Cancer Inst. 70:9–16.
1983.PubMed/NCBI
|
|
22
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai
P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of
CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sugihara E and Saya H: Complexity of
cancer stem cells. Int J Cancer. 132:1249–1259. 2013. View Article : Google Scholar
|
|
29
|
Freitas DP, Teixeira CA, Santos-Silva F,
Vasconcelos MH and Almeida GM: Therapy-induced enrichment of
putative lung cancer stem-like cells. Int J Cancer. 134:1270–1278.
2014. View Article : Google Scholar
|
|
30
|
Ratajczak M, Tarnowski M, Staniszewska M,
Sroczynski T and Banach B: Mechanisms of cancer metastasis:
Involvement of cancer stem cells? Minerva Med. 101:179–191.
2010.PubMed/NCBI
|
|
31
|
Chen X, Rycaj K, Liu X and Tang DG: New
insights into prostate cancer stem cells. Cell Cycle. 12:579–586.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rane JK, Scaravilli M, Ylipää A, Pellacani
D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T and
Maitland NJ: MicroRNA expression profile of primary prostate cancer
stem cells as a source of biomarkers and therapeutic targets. Eur
Urol. 67:7–10. 2015. View Article : Google Scholar
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
Han M, Partin AW, Zahurak M, Piantadosi S,
Epstein JI and Walsh PC: Biochemical (prostate specific antigen)
recurrence probability following radical prostatectomy for
clinically localized prostate cancer. J Urol. 169:517–523. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brookman-Amissah N, Nariculam J, Freeman
A, Willamson M, Kirby RS, Masters JR and Feneley MR: Allelic
imbalance at 13q14.2 approximately q14.3 in localized prostate
cancer is associated with early biochemical relapse. Cancer Genet
Cytogenet. 179:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Barron N, Keenan J, Gammell P, Martinez
VG, Freeman A, Masters JR and Clynes M: Biochemical relapse
following radical prostatectomy and miR-200a levels in prostate
cancer. Prostate. 72:1193–1199. 2012. View Article : Google Scholar
|
|
37
|
Li X, Liu Y, Chen W, Fang Y, Xu H, Zhu HH,
Chu M, Li W, Zhuang G and Gao WQ: TOP2Ahigh is the phenotype of
recurrence and metastasis whereas TOP2Aneg cells represent cancer
stem cells in prostate cancer. Oncotarget. 5:9498–9513. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kumar MS, Erkeland SJ, Pester RE, Chen CY,
Ebert MS, Sharp PA and Jacks T: Suppression of non-small cell lung
tumor development by the let-7 microRNA family. Proc Natl Acad Sci
USA. 105:3903–3908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mayr C, Hemann MT and Bartel DP:
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic
transformation. Science. 315:1576–1579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim HH, Kuwano Y, Srikantan S, Lee EK,
Martindale JL and Gorospe M: HuR recruits let-7/RISC to repress
c-Myc expression. Genes Dev. 23:1743–1748. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Barh D, Malhotra R, Ravi B and Sindhurani
P: MicroRNA let-7: An emerging next-generation cancer therapeutic.
Curr Oncol. 17:70–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Landi MT, Zhao Y, Rotunno M, Koshiol J,
Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola
FM, et al: MicroRNA expression differentiates histology and
predicts survival of lung cancer. Clin Cancer Res. 16:430–441.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Childs G, Fazzari M, Kung G, Kawachi N,
Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV,
Prystowsky MB, et al: Low-level expression of microRNAs let-7d and
miR-205 are prognostic markers of head and neck squamous cell
carcinoma. Am J Pathol. 174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Helland Å, Anglesio MS, George J, Cowin
PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk
N, Rustgi AK, et al: Australian Ovarian Cancer Study Group:
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of
aggressive high-grade serous ovarian cancers. PLoS One.
6:e180642011. View Article : Google Scholar
|
|
45
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J, et al: let-7 regulates self
renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kong D, Banerjee S, Ahmad A, Li Y, Wang Z,
Sethi S and Sarkar FH: Epithelial to mesenchymal transition is
mechanistically linked with stem cell signatures in prostate cancer
cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Viswanathan SR, Daley GQ and Gregory RI:
Selective blockade of microRNA processing by Lin28. Science.
320:97–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang X, Lin X, Zhong X, Kaur S, Li N,
Liang S, Lassus H, Wang L, Katsaros D, Montone K, et al:
Double-negative feedback loop between reprogramming factor LIN28
and microRNA let-7 regulates aldehyde dehydrogenase 1-positive
cancer stem cells. Cancer Res. 70:9463–9472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhong X, Li N, Liang S, Huang Q, Coukos G
and Zhang L: Identification of microRNAs regulating reprogramming
factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem.
285:41961–41971. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ji J and Wang XW: A Yin-Yang balancing act
of the lin28/let-7 link in tumorigenesis. J Hepatol. 53:974–975.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
King CE, Cuatrecasas M, Castells A,
Sepulveda AR, Lee JS and Rustgi AK: LIN28B promotes colon cancer
progression and metastasis. Cancer Res. 71:4260–4268. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Peter ME: Let-7 and miR-200 microRNAs:
Guardians against pluripotency and cancer progression. Cell Cycle.
8:843–852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Esquela-Kerscher A, Trang P, Wiggins JF,
Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG and
Slack FJ: The let-7 microRNA reduces tumor growth in mouse models
of lung cancer. Cell Cycle. 7:759–764. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kleinberg DL, Feldman M and Ruan W: IGF-I:
An essential factor in terminal end bud formation and ductal
morphogenesis. J Mammary Gland Biol Neoplasia. 5:7–17. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pacher M, Seewald MJ, Mikula M, Oehler S,
Mogg M, Vinatzer U, Eger A, Schweifer N, Varecka R, Sommergruber W,
et al: Impact of constitutive IGF1/IGF2 stimulation on the
transcriptional program of human breast cancer cells.
Carcinogenesis. 28:49–59. 2007. View Article : Google Scholar
|
|
56
|
Kang BP, Urbonas A, Baddoo A, Baskin S,
Malhotra A and Meggs LG: IGF-1 inhibits the mitochondrial apoptosis
program in mesangial cells exposed to high glucose. Am J Physiol
Renal Physiol. 285:F1013–F1024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wei L, Xiao AY, Jin C, Yang A, Lu ZY and
Yu SP: Effects of chloride and potassium channel blockers on
apoptotic cell shrinkage and apoptosis in cortical neurons.
Pflugers Arch. 448:325–334. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jin C and Guo J, Qiu X, Ma K, Xiang M, Zhu
X and Guo J: IGF-1 induces iNOS expression via the p38 MAPK signal
pathway in the anti-apoptotic process in pulmonary artery smooth
muscle cells during PAH. J Recept Signal Transduct Res. 34:325–331.
2014. View Article : Google Scholar : PubMed/NCBI
|
